COMy 2023 | Lenalidomide maintenance therapy in patients with multiple myeloma and high-risk cytogenetics
The use of lenalidomide as maintenance therapy after autologous stem cell transplantation (autoSCT) in patients with high-risk multiple myeloma is currently debated in the clinical field. In this video, Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, comments on the potential benefits of lenalidomide maintenance in this patient population, based on results from a post-hoc analysis conducted by the Myeloma UK group. Dr Mateos also discusses the importance of exploring novel approaches for patients presenting with two or more high-risk cytogenetic abnormalities. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
